Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Astrofísico Fco. Sánchez, S/N, La Laguna, Tenerife, 38203 Islas Canarias, Spain; Departamento de Obstetricia, Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad De La Laguna, La Laguna, Tenerife, 38203 Islas Canarias, Spain.
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Astrofísico Fco. Sánchez, S/N, La Laguna, Tenerife, 38203 Islas Canarias, Spain; Departamento de Obstetricia, Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad De La Laguna, La Laguna, Tenerife, 38203 Islas Canarias, Spain; Red de Investigación Colaborativa en Enfermedades Tropicales (RICET), Spain.
Biomed Pharmacother. 2020 Oct;130:110583. doi: 10.1016/j.biopha.2020.110583. Epub 2020 Jul 31.
Naegleria fowleri is the causative agent of a type of encephalitis called Primary Amoebic Encephalitis (PAM). Almost 98 % of PAM cases reported worldwide are fatal and affect mostly immunocompetent children and young adults. The current therapeutic option against PAM cases includes a combination of miltefosine, amphotericin B and other drugs which are unfortunately associated with severe side effects. In a recent study in our group, statins were tested in vitro against Naegleria fowleri trophozoites showing activity against these pathogens at low concentrations causing low toxicity. Consequently, there is an urgent need to develop novel PAM therapeutic options. Therefore, this study was undertaken to evaluate the pathway of cell death induced by two of the previously tested molecules, fluvastatin and atorvastatin. Moreover, these statins were compared to miltefosine and amphotericin B. Furthermore, the induction of Programmed Cell Death (PCD) instead of necrosis in treated amoebae would be the ideal situation since necrosis could lead to non-desired inflammation processes in the infected individual. The obtained results revealed that both statins induced PCD in the treated amoebae after the observation of condensed chromatin, cell membrane damages, mitochondrial membrane potential and ATP levels collapse and ROS generation. In conclusion, both fluvastatin and atorvastatin could be potential new candidates for PAM therapy since they are active at low concentrations, induce low toxicity and cause PCD in the treated amoebae, hence avoiding the activation of inflammation pathways.
福氏耐格里阿米巴是一种脑炎的病原体,称为原发性阿米巴脑膜脑炎(PAM)。全世界报告的 PAM 病例中,几乎有 98%是致命的,主要影响免疫功能正常的儿童和年轻成年人。目前针对 PAM 病例的治疗选择包括米替福新、两性霉素 B 和其他药物的联合治疗,但不幸的是,这些药物与严重的副作用有关。在我们小组最近的一项研究中,他汀类药物在体外对福氏耐格里阿米巴滋养体进行了测试,结果表明这些药物在低浓度下对这些病原体具有活性,同时毒性较低。因此,迫切需要开发新的 PAM 治疗选择。因此,本研究旨在评估先前测试的两种分子(氟伐他汀和阿托伐他汀)诱导细胞死亡的途径。此外,还将这些他汀类药物与米替福新和两性霉素 B 进行了比较。此外,诱导程序性细胞死亡(PCD)而不是处理后的变形虫坏死将是理想的情况,因为坏死可能导致感染个体中产生非预期的炎症过程。研究结果表明,两种他汀类药物在观察到浓缩染色质、细胞膜损伤、线粒体膜电位和 ATP 水平崩溃以及 ROS 生成后,均可诱导处理后的变形虫发生 PCD。总之,氟伐他汀和阿托伐他汀都可能成为 PAM 治疗的潜在新候选药物,因为它们在低浓度下具有活性,诱导低毒性,并导致处理后的变形虫发生 PCD,从而避免炎症途径的激活。